Product Description: Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor[1][2].
Applications: COVID-19-anti-virus
Formula: C15H13F3N2O2
References: [1]Thomson TA, et al. In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine. Scand J Immunol. 2002 Jul;56(1):35-42./[2]Curnock AP, et al. Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1997 Jul;282(1):339-47.
CAS Number: 147076-36-6
Molecular Weight: 310.27
Compound Purity: 99.76
Research Area: Inflammation/Immunology
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Dihydroorotate Dehydrogenase;DNA/RNA Synthesis;Prostaglandin Receptor
Deutsch
English
